NasdaqGM - Nasdaq Real Time Price USD

Axsome Therapeutics, Inc. (AXSM)

71.71

+0.19

(+0.27%)

At close: April 26 at 4:00 PM EDT

72.25

+0.54

(+0.75%)

After hours: April 26 at 6:48 PM EDT

15 Most Black States in the US

In this article, we will be taking a look at the 15 most black states in the US. If you do not want to learn about the demographics of global black population, head straight to the 5 Most Black States in the US. Overview of the Global Black Population: Demographics, Trends, and Immigration Patterns The […]

Insider Monkey 6 days ago

UONEK

BYFC

AXSM
+0.27%
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative p

GlobeNewswire 13 days ago

AXSM
+0.27%
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and

GlobeNewswire 18 days ago

AXSM
+0.27%
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

Zacks 26 days ago

AXSM
+0.27%
ANIP
Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics Inc (NASDAQ:AXSM), a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS) disorders, has reported an insider sell according to a recent SEC filing.

GuruFocus.com 26 days ago

AXSM
+0.27%
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults. ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blin

GlobeNewswire 27 days ago

AXSM
+0.27%
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them. These three strong buy biotech stocks are joining the upper ranks of their industry with promising new drugs and encouraging financials that justify serious consideration. Given the timeline of clinical trials and new rele

InvestorPlace last month

AXSM
+0.27%
KRYS

CPRX
30 Countries with the Lowest Depression Rates

In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]

Insider Monkey last month

VTGN

AXSM
+0.27%
20 Cloudiest Cities in the U.S., Ranked

In this article, we will take a look at the top 20 cloudiest cities in the U.S., Ranked. If you would like to skip our discussion on the diverse weather patterns across the country, you can go to the 5 Cloudiest Cities in the U.S., Ranked. Ranking fourth in terms of land area globally, the […]

Insider Monkey last month

JNJ

ABBV

AXSM
+0.27%
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI) Depression and anxiety were experienced by 45% and 57% of narcolepsy type 1 patients, respectiv

GlobeNewswire last month

AXSM
+0.27%
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) AXS-12 statistically significantly reduced excessive daytime sleepiness (EDS) severity compared to placebo (p=0.027, CGI-S for EDS) AXS-12 statistically significantly improved concentration and memory compared to placebo (p=0.004, Cognitive Function items of FOSQ-10) AXS-12 statistically signifi

GlobeNewswire last month

AXSM
+0.27%
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

The price could be right for these three biopharma stocks.

Motley Fool last month

PFE

CRSP

AXSM
+0.27%
Axsome Triumphs Over Major Depressive Disorder With Auvelity

A closer look at one of the leaders in the global central nervous system therapeutics market

GuruFocus.com last month

AXSM
+0.27%
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.

Zacks last month

ANIP

ADMA

AXSM
+0.27%
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder (MDD). PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized,

GlobeNewswire last month

AXSM
+0.27%
11 Oversold NASDAQ Stocks To Buy Right Now

In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads The Market On March 12, the Nasdaq Composite Index was […]

Insider Monkey last month

COMP

PACB

APPS
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, at 9:20 a.m. Eastern Time at the Fontainebleau in Miami Beach, Florida. A live webcast and a

GlobeNewswire last month

AXSM
+0.27%
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, from 9:50-10:20 a.m. Eastern Time at the Marriott Copley Place in Boston, Massachusetts. A live

GlobeNewswire last month

AXSM
+0.27%
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024

The biotech sector is in the spotlight in 2024, where under-the-radar biotech stocks with upcoming catalysts could offer significant upside. Analysts are projecting an acceleration in new drug approvals as demand for effective treatments for chronic diseases continues to increase. Biotech companies developing therapeutics in gene therapy, obesity, oncology, and immunology are attracting significant investor attention as potential growth drivers. Yet, the iShares Biotechnology ETF (NASDAQ:IBB) ha

InvestorPlace 2 months ago

IOVA
+0.87%
IMVT

AXSM
+0.27%
3 Biotech Stocks to Buy and Hold for the Next 10 Years

There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.

Motley Fool 2 months ago

AMGN

CRSP

AXSM
+0.27%

Performance Overview

Return	AXSM	S&P 500
YTD	-9.90%	+6.92%
1-Year	+0.67%	+25.26%
3-Year	+35.58%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Axsome Therapeutics, Inc. (AXSM)

15 Most Black States in the US

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

30 Countries with the Lowest Depression Rates

20 Cloudiest Cities in the U.S., Ranked

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Axsome Triumphs Over Major Depressive Disorder With Auvelity

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

11 Oversold NASDAQ Stocks To Buy Right Now

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024

3 Biotech Stocks to Buy and Hold for the Next 10 Years

Performance Overview